{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:53:24Z","timestamp":1791140004437,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejca.2023.113420","type":"journal-article","created":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T10:29:43Z","timestamp":1699180183000},"page":"113420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Patient-reported outcomes in high-risk HR+\u00a0\/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study"],"prefix":"10.1016","volume":"196","author":[{"given":"Jos\u00e9 Angel","family":"Garc\u00eda-S\u00e1enz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6591-3367","authenticated-orcid":false,"given":"Frederik","family":"Marm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Bonnefoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Bear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mc Carthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Gelmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3014-370X","authenticated-orcid":false,"given":"Toralf","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1002-2118","authenticated-orcid":false,"given":"Michael","family":"Gnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Makris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-033X","authenticated-orcid":false,"given":"Sabine","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Burchardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2801-7387","authenticated-orcid":false,"given":"Valentina","family":"Nekljudova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-4958","authenticated-orcid":false,"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ejca.2023.113420_bib1","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejca.2023.113420_bib2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2023.113420_bib3","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-22-0305","article-title":"Overall survival with palbociclib and fulvestrant in women with HR+\/HER2- ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study","volume":"28","author":"Cristofanilli","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2023.113420_bib4","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113420_bib5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113420_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: A phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2023.113420_bib7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ejca.2023.113420_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41523-021-00289-7","article-title":"Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups","volume":"7","author":"Johnston","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2023.113420_bib9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10549-019-05433-3","article-title":"The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors","volume":"178","author":"de Ligt","year":"2019","journal-title":"Breast Canc Res Treat"},{"issue":"Suppl 6","key":"10.1016\/j.ejca.2023.113420_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1634\/theoncologist.2002-0013","article-title":"Combination versus sequential single-agent therapy in metastatic breast cancer","volume":"7","author":"Miles","year":"2002","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ejca.2023.113420_bib11","first-page":"549","article-title":"Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications","volume":"25","author":"Stefanovic","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2023.113420_bib12","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.20.03639","article-title":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer\u2014the Penelope-B trial","volume":"39","author":"Loibl","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2023.113420_bib13","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.113420_bib14","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/annonc\/mdy012","article-title":"Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","volume":"29","author":"Rugo","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.113420_bib15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113420_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2021.07.004","article-title":"Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study","volume":"156","author":"Kahan","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2023.113420_bib17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-018-4769-z","article-title":"Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib\u2009+\u2009letrozole: results from MONALEESA-2","volume":"170","author":"Verma","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2023.113420_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920943065","article-title":"Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)","volume":"12","author":"Harbeck","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2023.113420_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2023.113420_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.10.003","article-title":"Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research","volume":"118","author":"Giesinger","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.ejca.2023.113420_bib21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00439229","article-title":"The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30","volume":"5","author":"King","year":"1996","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.ejca.2023.113420_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2023.113420_bib23","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.ejca.2008.05.008","article-title":"Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 data in randomised controlled trials","volume":"44","author":"Cocks","year":"2008","journal-title":"Eur J Cancer"},{"issue":"Issue 3","key":"10.1016\/j.ejca.2023.113420_bib24","doi-asserted-by":"crossref","first-page":"pkz037","DOI":"10.1093\/jncics\/pkz037","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer","volume":"Volume 3","author":"Musoro","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ejca.2023.113420_bib25","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2023.113420_bib26","first-page":"359","article-title":"Longitudinal effects of adjuvant endocrine therapy on the quality of life of post-menopausal women with non-metastatic ER+ breast cancer: a systematic review","volume":"2","author":"Xiao","year":"2018","journal-title":"Pharm Open"},{"issue":"4","key":"10.1016\/j.ejca.2023.113420_bib27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4274\/ejbh.galenos.2022.2022-5-8","article-title":"Health-related quality of life in women with breast cancer undergoing treatment with hormonal therapy - a review study","volume":"18","author":"Alnaim","year":"2022","journal-title":"Eur J Breast Health"},{"issue":"6","key":"10.1016\/j.ejca.2023.113420_bib28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/CCO.0000000000000781","article-title":"Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy","volume":"33","author":"Di Meglio","year":"2021","journal-title":"Curr Opin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:39Z","timestamp":1760733759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923007220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":28,"alternative-id":["S0959804923007220"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113420","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes in high-risk HR+\u00a0\/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113420"}}